Information  X 
Enter a valid email address

Shield Therapeutics (STX)

  Print   

Monday 21 June, 2021

Shield Therapeutics

Investor presentation

RNS Number : 5290C
Shield Therapeutics PLC
21 June 2021
 

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

 

Investor presentation

 

London, UK, 21 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Greg Madison, Chief Executive Officer, will present at the OTCQX Life Science Virtual Investor Forum at 3.00pm BST  (10am EST) on Thursday, 24 June 2021.

 

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

 

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates . Investors can register to attend here:  https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-1

 

No new material information will be disclosed at the event.    

 

 

For further information, please contact:

 

Shield Therapeutics plc

+44 (0) 191 511 8500

Greg Madison (CEO)

Hans-Peter Rudolf (CFO)




Peel Hunt LLP - Nominated Adviser and Joint Broker

  +44 (0) 20 7148 8900

James Steel / Christopher Golden




finnCap Ltd - Joint Broker

  +44 (0) 20 7220 0500

Geoff Nash / Alice Lane / Matthew Radley




Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne

or [email protected]

 

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFBMPTMTBTMJB

a d v e r t i s e m e n t